Foundation Fighting Blindness Retinal Degeneration Fund - 05 May 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Role
Director, Other*, 10%+ Owner
Signature
Foundation Fighting Blindness Retinal Degeneration Fund, By: /s/ Lorna A. Knick, Attorney-in-Fact for Russell Kelley
Issuer symbol
IRD
Transactions as of
05 May 2025
Net transactions value
$0
Form type
4
Filing time
06 May 2025, 18:05:27 UTC
Previous filing
29 Oct 2024
Next filing
11 Dec 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Foundation Fighting Blindness Retinal Degeneration Fund Director, Other*, 10%+ Owner 223 S. WEST STREET, SUITE 900, RALEIGH Foundation Fighting Blindness Retinal Degeneration Fund, By: /s/ Lorna A. Knick, Attorney-in-Fact for Russell Kelley 06 May 2025 0002042266
Foundation Fighting Blindness, Inc. Director, Other*, 10%+ Owner 6925 OAKLAND MILLS ROAD, #701, COLUMBIA Foundation Fighting Blindness, Inc. By: /s/ Lorna A. Knick, Attorney-in-Fact for Jason Menzo 06 May 2025 0002042532

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRD Common Stock Conversion of derivative security +6,927,419 +270% 9,492,171 05 May 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRD Series A Non-Voting Convertible Preferred Stock Conversion of derivative security -6,927 -100% 0 05 May 2025 Common Stock 6,927,419 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A non-voting convertible preferred stock (the "Preferred Stock") automatically converted into 1,000 shares of the Issuer's common stock as of 5:00 p.m. Eastern time on the third business day after the date that the Issuer's stockholders approved the conversion of the Preferred Stock into shares of the Issuer's common stock, which approval occurred on April 30, 2025.
F2 Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.
F3 The shares of Preferred Stock were issued to the Reporting Persons in connection with a merger and reorganization in a stock-for-stock transaction.

Remarks:

For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF. FFB is the sole member of RDF and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.